SAN

81.78

+0.01%↑

MRK1

119.25

+0.72%↑

SHL.DE

44.63

+1.2%↑

ARGX

726.6

-1.14%↓

FRE

47.94

+0.57%↑

SAN

81.78

+0.01%↑

MRK1

119.25

+0.72%↑

SHL.DE

44.63

+1.2%↑

ARGX

726.6

-1.14%↓

FRE

47.94

+0.57%↑

SAN

81.78

+0.01%↑

MRK1

119.25

+0.72%↑

SHL.DE

44.63

+1.2%↑

ARGX

726.6

-1.14%↓

FRE

47.94

+0.57%↑

SAN

81.78

+0.01%↑

MRK1

119.25

+0.72%↑

SHL.DE

44.63

+1.2%↑

ARGX

726.6

-1.14%↓

FRE

47.94

+0.57%↑

SAN

81.78

+0.01%↑

MRK1

119.25

+0.72%↑

SHL.DE

44.63

+1.2%↑

ARGX

726.6

-1.14%↓

FRE

47.94

+0.57%↑

Search

Laboratorios Farmaceuticos Rovi SA

Ouvert

SecteurSoins de santé

61.5 0.82

Résumé

Variation du prix de l'action

24h

Actuel

Min

60.8

Max

62.2

Chiffres clés

By Trading Economics

Revenu

49M

76M

Ventes

51M

210M

P/E

Moyenne du Secteur

26.54

76.798

BPA

1.135

Rendement du dividende

1.5

Marge bénéficiaire

35.965

Employés

2,197

EBITDA

49M

84M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+48.51% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.50%

2.37%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-18M

3.2B

Ouverture précédente

60.68

Clôture précédente

61.5

Sentiment de l'Actualité

By Acuity

50%

50%

167 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 déc. 2025, 23:54 UTC

Actions en Tendance

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 déc. 2025, 23:51 UTC

Résultats

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 déc. 2025, 23:39 UTC

Principaux Mouvements du Marché

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 déc. 2025, 22:57 UTC

Acquisitions, Fusions, Rachats

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 déc. 2025, 21:40 UTC

Résultats

Nike Sales Tick Up, But China Weakness Persists

18 déc. 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 déc. 2025, 23:37 UTC

Market Talk
Résultats

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 déc. 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 déc. 2025, 23:03 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 déc. 2025, 23:02 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 déc. 2025, 23:00 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 déc. 2025, 22:59 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 déc. 2025, 22:58 UTC

Acquisitions, Fusions, Rachats

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 déc. 2025, 22:57 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 déc. 2025, 22:56 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 déc. 2025, 22:55 UTC

Résultats

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 déc. 2025, 21:59 UTC

Résultats

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 déc. 2025, 21:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

18 déc. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 déc. 2025, 21:35 UTC

Résultats

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 déc. 2025, 21:31 UTC

Résultats

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Greater China Rev Down 17% >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q EPS 53c >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Apparel Rev $3.91B >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Equipment Rev $550M >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q N Amer Rev $5.63B >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Footwear Rev $7.66B >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Greater China Rev $1.42B >NKE

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

48.51% hausse

Prévisions sur 12 Mois

Moyen 90 EUR  48.51%

Haut 90 EUR

Bas 90 EUR

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

167 / 374Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat